266 related articles for article (PubMed ID: 27126691)
41. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation.
Hebestreit H; Sauer-Heilborn A; Fischer R; Käding M; Mainz JG
J Cyst Fibros; 2013 Dec; 12(6):599-603. PubMed ID: 23757359
[TBL] [Abstract][Full Text] [Related]
42. Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up.
Fila L; Valentova Bartakova L; Grandcourtova A; Marel M; Drnek R; Bilkova A; Macek M; Drevinek P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun; 160(2):276-9. PubMed ID: 27226150
[TBL] [Abstract][Full Text] [Related]
43. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
[TBL] [Abstract][Full Text] [Related]
44. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.
Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T
J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177
[TBL] [Abstract][Full Text] [Related]
45. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS
J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519
[TBL] [Abstract][Full Text] [Related]
46. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.
Konstan MW; Plant BJ; Elborn JS; Rodriguez S; Munck A; Ahrens R; Johnson C
Pediatr Pulmonol; 2015 May; 50(5):447-55. PubMed ID: 25755212
[TBL] [Abstract][Full Text] [Related]
47. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
[TBL] [Abstract][Full Text] [Related]
48. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
[TBL] [Abstract][Full Text] [Related]
49. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
50. Ivacaftor for cystic fibrosis: An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting.
Corcoran A; Hickey N; Barry M; Usher C; McCullagh LM
Ir Med J; 2017 Aug; 110(7):619. PubMed ID: 29169001
[TBL] [Abstract][Full Text] [Related]
51. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
52. Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid.
Mainz JG; Arnold C; Wittstock K; Hipler UC; Lehmann T; Zagoya C; Duckstein F; Ellemunter H; Hentschel J
Front Immunol; 2021; 12():642180. PubMed ID: 34025651
[TBL] [Abstract][Full Text] [Related]
53. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE; Elborn JS; Ramsey BW; Marigowda G; Huang X; Cipolli M; Colombo C; Davies JC; De Boeck K; Flume PA; Konstan MW; McColley SA; McCoy K; McKone EF; Munck A; Ratjen F; Rowe SM; Waltz D; Boyle MP; ;
N Engl J Med; 2015 Jul; 373(3):220-31. PubMed ID: 25981758
[TBL] [Abstract][Full Text] [Related]
54. Ivacaftor in People with Cystic Fibrosis and a
Kerem E; Cohen-Cymberknoh M; Tsabari R; Wilschanski M; Reiter J; Shoseyov D; Gileles-Hillel A; Pugatsch T; Davies JC; Short C; Saunders C; DeSouza C; Sullivan JC; Doyle JR; Chandarana K; Kinnman N
Ann Am Thorac Soc; 2021 Mar; 18(3):433-441. PubMed ID: 33095038
[No Abstract] [Full Text] [Related]
55. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
56. Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
McGarry LJ; Bhaiwala Z; Lopez A; Chandler C; Pelligra CG; Rubin JL; Liou TG
PLoS One; 2023; 18(4):e0283479. PubMed ID: 37043485
[TBL] [Abstract][Full Text] [Related]
57. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis.
Putman MS; Greenblatt LB; Bruce M; Joseph T; Lee H; Sawicki G; Uluer A; Sicilian L; Neuringer I; Gordon CM; Bouxsein ML; Finkelstein JS
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1248-e1261. PubMed ID: 33258950
[TBL] [Abstract][Full Text] [Related]
58. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
59. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
Taylor-Cousar J; Niknian M; Gilmartin G; Pilewski JM;
J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
[TBL] [Abstract][Full Text] [Related]
60. Longitudinal effects of ivacaftor and medicine possession ratio in people with the
Mitchell RM; Jones AM; Stocking K; Foden P; Barry PJ
Thorax; 2021 Sep; 76(9):874-879. PubMed ID: 33579778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
